ReviewEuropean journal of rheumatology2018
Semaphorin3A: A potential therapeutic tool in immune-mediated diseases.
Review in European journal of rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Causal Relationships Between Environmental Exposures, Iron Metabolism, Hematuria Markers, and Rheumatoid Arthritis: An Investigation Using Mendelian Randomization.Biomedicines · 2025Article
- Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression.Inflammopharmacology · 2024Article
- Semaphorin 3 a restores the ability of type 1 regulatory T cells to suppress food allergy.Immunologic research · 2024Article
- Pure platelet-rich plasma promotes semaphorin-3A expression: a novel insight to ameliorate intervertebral disk degeneration in vitro.Journal of orthopaedic surgery and research · 2023Article
- Increased Epidermal Nerve Growth Factor without Small-Fiber Neuropathy in Dermatomyositis.International journal of molecular sciences · 2022Article
- Semaphorin 3A in the Immune System: Twenty Years of Study.Biochemistry. Biokhimiia · 2022Review
- Semaphorin-3A: a promising therapeutic tool in allergic rhinitis.Immunologic research · 2022Review
- Activity-induced secretion of semaphorin 3A mediates learning.The European journal of neuroscience · 2021Article
- Review
- The Role of Semaphorins and Their Receptors in Innate Immune Responses and Clinical Diseases of Acute Inflammation.Frontiers in immunology · 2021Review
- Differences in immune-related semaphorin levels in the CSF and serum of newly diagnosed, treatment-naive patients with relapsing-remitting multiple sclerosis: a case-control study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The significance of semaphorin3A (sema3A) in regulating immune-mediated inflammation is widely reported. There are multiple mechanisms involved in the process of sema3A-mediated regulation. One of them is the ability of sema3A to maintain a sufficient regulation of both T-cell and B-cell activation. Because it is involved in the pathogenesis of many autoimmune, infectious, and malignant diseases, sema3A turns to be a promising therapeutic tool to be studied and applied in these diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.